Navigation Links
Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
Date:4/30/2008

Dr. Bill Poland Will Present on the Strategic Use of Incorporating Adherence Data into Clinical Trial Predictions of Antiviral Therapies

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, has been invited to present at a Drug Information Association (DIA) workshop on using patient adherence data at the University of California Washington Center in Washington, DC. Dr. Poland will present on May 6, 2008, joining other leading experts from the pharmaceutical industry and academia in a session on the utility of incorporating adherence estimates in the design of clinical trials intended to learn about exposure-response relationships.

The workshop will provide a forum for scientific discussion and collaborative exchange on opportunities for the use of new methods in the conduct and interpretation of clinical trials through the use of reliable patient adherence data. Dr. Poland's presentation, entitled "Incorporating Adherence into Antiviral Clinical Trial Predictions", will describe how quantitative models of patient compliance for new antiviral agents can be linked with predictive drug-disease models to optimize dosing strategies and support clinical trial simulations. Further information can be found at http://www.diahome.org.

"Antiviral drugs present special therapeutic challenges to development teams, including patient compliance with long-term treatment regimens," said Shawn O'Connor, president, CE
'/>"/>

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Pharsight Strengthens Senior Management Team
2. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
3. Pharsight Signs New Diabetes Meta-Database Customer
4. Pharsight to Present at eClinical Forum
5. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
6. FDA and Pharsight Continue to Collaborate Under CRADA
7. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
8. Pharsight Achieves $7.3 Million in Quarterly Revenue
9. Pharsight Expands Global Consulting Services Teams
10. Pharsight to Host European Software Conference
11. Pharsight Files Application for Nasdaq Capital Market Listing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2009)...s were more likely to consider change after 30-min... , FRIDAY, Nov. 27 (HealthDay News) -- A progr...why they should stop their dangerous behavior may ...archers have found. , The new study included 18...aired convictions, who were randomly assigned to o...
(Date:11/27/2009)...WNA, BC, Nov. 27 /PRNewswire/ - Uploadable USB ped...me time in wellness. A combination of advanced acc... are solving a long term concern over the accuracy...ately gauge and reward improved participation in a... one of the first wellness suppliers to integrate ...
(Date:11/27/2009)...HESTER, N.Y., Nov. 27 P... provider and fortunately every year, new vaccines...But do all vaccines boost immunity for the same pe...oster shots, needed to keep immunity strong? ,...l of the American Academy of Pediatrics, Michael P...
(Date:11/27/2009)...ling plus low-emission vehicles may reduce future ...AY, Nov. 27 (HealthDay News) -- Encouraging city d...would offer much greater public health benefits th...esearchers have found. , The study compared the...rban land transport scenarios for London, England,...
(Date:11/27/2009)... Multi-purpose bilingual coloring books ...se by the business community to educate - inform p... from Safety issues to Dinosuars to ABC,S and a ho...nt Louis, MO (PRWEB) November 27, 2009 -- Today&rs... toys to keep them busy any hour of the day, but o...
Breaking Medicine News(10 mins):Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:New USB technology adds accountability and convenience to wellness programs 2Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2
..., Safety and Efficacy Study of Zolpidem Tartrate S...wakening on an As-Needed Basis , , Evaluation of ...sive Compulsive Disorder , , RICHMOND, Calif., Ma...etary products that address important therapeutic ...
..., Videotape The Silliest Sneeze You,ve Ever Seen F...Little Allergies(R) Allergen Block! , , Contest E....Y., May 21 Do your friends, family, or coworkers...Allergen Block , announce the launch of the first ...
...Procedure doubles odds for intensive care compared... , THURSDAY, May 21 (HealthDay News) -- Babies...livery are nearly twice as likely to be admitted t...ion babies are also more likely to have breathing ...
..., LAS VEGAS, May 21 CPC of America, Inc. (OTC Bul...of its first patent of a synthetic sealant for spe... focused on the development and testing of the Med...on, CPC is focused on the development of its own s...
..., PRINCETON, N.J., May 21 Celator Pharmaceuticals...ch agreement with Cephalon, Inc. (Nasdaq: CEPH )...tion of the application of Celator,s proprietary t...echnology and expertise at Celator beyond our own ...
..., - Bold and innovative marketing campaign will ta...of use and excellent tolerability - , , CORONA, C...in generic and specialty branded pharmaceuticals, ...h symptoms of urge urinary incontinence, urgency, ...
Other Medicine News:Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 2Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 3Health News:Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association 4Health News:If Heads Turn When You Sneeze, Enter the 'Side-Splitting Sneeze Contest' 2Health News:Risk to Baby Rises With Repeat C-Sections 2Health News:Risk to Baby Rises With Repeat C-Sections 3Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc. 2Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 2Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 3Health News:Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB) 4
(Date:11/26/2009)...frica, Nov. 26 The 2009 Frost &...in the Generic Pharmaceutical Market is presented ... http://www.newscom.com/cgi-bin/prnh/20081117/FSL... following criteria were used to benchmark Cipla M...h strategy and implementation, degree of innovatio...
(Date:11/25/2009)...25 American Scientific R...is pleased to announce that they have opened a reg...n Shanghai, China. ,, ASR has been able to secu...ay for the development and production of current a...and adults to be distributed and sold globally. C...
(Date:11/25/2009)...5 Hologic, Inc. (Hologic...oper, manufacturer and supplier of premium diagnos...s dedicated to serving the healthcare needs of wom...l Society of North America (RSNA) at McCormick Pla...9 to highlight our new SecurView(®) DX multim...
Breaking Medicine Technology:Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 2Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 3Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market 4American Scientific Resources Inc. Opens Shanghai Location 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 1Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 2Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 3Cell Therapeutics Amends and Restates Its Modified Dutch Auction Tender Offer to a Fixed Price Tender Offer for Any and All of Its 24118 9 Million Ou 12433 4Bayer Diabetes Care Launches A1CNow 28R 29 SELFCHECK a New A1C Monitor for At Home Use 47720 1Bayer Diabetes Care Launches A1CNow 28R 29 SELFCHECK a New A1C Monitor for At Home Use 47720 2Bayer Diabetes Care Launches A1CNow 28R 29 SELFCHECK a New A1C Monitor for At Home Use 47720 3Bayer Diabetes Care Launches A1CNow 28R 29 SELFCHECK a New A1C Monitor for At Home Use 47720 4Scientists create metal that pumps liquid uphill 12431 1Scientists create metal that pumps liquid uphill 12431 2Scientists create metal that pumps liquid uphill 12431 3
...ODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - Rep...nal results of a U.S.,Phase 2 study of Proellex(TM...s of uterine fibroids. This study suggests that,tr...ighly,significant improvement in symptoms associat...erated., Study Details and Results , This 12 week,...
...gs indicate early non-responders unlikely to subse... costs, and may benefit,from earlier change in tre..., 2007 /PRNewswire-FirstCall/,-- New data presente...nia Research (ICOSR) suggest that antipsychotic dr...thought, and,challenge the current schizophrenia t...
Other Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6
Reusable Template
MicroTouch LP (Low Profile) Stabilizer
Precision Stepper
SurePoint™ Stepper/Stabilizer EquipmentTable Mount
Medicine Products: